These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22453192)

  • 1. Safety learning from drugs of the same class: room for improvement.
    Stefansdottir G; Knol MJ; Arnardottir AH; van der Elst ME; Grobbee DE; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2012 May; 91(5):872-80. PubMed ID: 22453192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
    J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
    Ortega A; Aguinagalde A; Lacasa C; Aquerreta I; Fernández-Benítez M; Fernández LM
    Ann Pharmacother; 2008 Oct; 42(10):1491-6. PubMed ID: 18780808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac adverse effects associated with psychotropic drugs.
    Schmid C; Grohmann R; Engel RR; Rüther E; Kropp S
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S65-9. PubMed ID: 15052516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?
    Aagaard L; Soendergaard B; Stenver DI; Hansen EH
    Br J Clin Pharmacol; 2008 Mar; 65(3):364-76. PubMed ID: 17961195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nurses are increasingly involved in pharmacovigilance in Sweden.
    Ulfvarson J; Mejyr S; Bergman U
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):532-7. PubMed ID: 17072915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug related hospital admissions in subspecialities of internal medicine.
    Hallas J
    Dan Med Bull; 1996 Apr; 43(2):141-55. PubMed ID: 8741207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential causal association mining algorithm for screening adverse drug reactions in postmarketing surveillance.
    Ji Y; Ying H; Dews P; Mansour A; Tran J; Miller RE; Massanari RM
    IEEE Trans Inf Technol Biomed; 2011 May; 15(3):428-37. PubMed ID: 21435986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of drug safety information using large-scale adverse drug reactions database].
    Morikawa K
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2011; (129):1-26. PubMed ID: 22259840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacovigilance of vaccines].
    Autret-Leca E; Bensouda-Grimaldi L; Jonville-Béra AP; Beau-Salinas F
    Arch Pediatr; 2006 Feb; 13(2):175-80. PubMed ID: 16343870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are novel drugs more risky for patients than less novel drugs?
    Olson MK
    J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The AMUP study for drug surveillance in psychiatry - a summary of inpatient data.
    Grohmann R; Hippius H; Helmchen H; Rüther E; Schmidt LG
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S16-26. PubMed ID: 15052511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacologic surveillance and safety evaluation of new drugs].
    Reys LL
    Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient reporting of adverse drug reactions: useful information for pain management?
    Jarernsiripornkul N; Krska J; Richards RM; Capps PA
    Eur J Pain; 2003; 7(3):219-24. PubMed ID: 12725844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing surveillance.
    Vlahović-Palčevski V; Mentzer D
    Handb Exp Pharmacol; 2011; 205():339-51. PubMed ID: 21882120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.